Tanya J McWilliams

Jul 11, 2024 | erj.ersjournals.com | Michael Plunkett |Tanya J McWilliams |Julian F.R. Paton |James Fisher

AcknowledgementsThe authors wish to thank all the volunteers for their valuable participation in this study, and Marie Mata for assistance with patient recruitment and study procedures. FootnotesThis clinical trial was prospectively registered as ACTRN12622000505707. Ethics statement: This study was approved by the Health and Disability Ethics Committee (HDEC 2022 FULL 12454).

Jan 4, 2024 | erj.ersjournals.com | Michael Plunkett |Tanya J McWilliams |Julian F.R. Paton |James Fisher

To the Editor:Impairment of exercise capacity, predominantly limited symptomatically by dyspnoea [1], affects most patients with pulmonary arterial hypertension (PAH) despite current therapies [2], with significant implication for patients, adversely impairing health-related quality of life [3] and clinical prognosis [4]. However, the underpinning physiological mechanisms behind dyspnoea and exercise limitation remain incompletely understood.

Sep 7, 2023 | erj.ersjournals.com | Michael Plunkett |Tanya J McWilliams |James Fisher

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Received June 6, 2023. Accepted August 17, 2023.